QTI:NASDAQQT Imaging Holdings, Inc. Analysis
Data as of 2026-06-13 - not real-time
$4.04
Latest Price
8/10Risk
Risk Level: High
Executive Summary
QT Imaging has demonstrated a dramatic revenue surge of 133% YoY, driven by 13 scanner shipments in Q1 2026 and a $10 million capital infusion from a recent public offering. The stock is trading at $4.04, well below the analyst median target of $11.60, implying an upside of roughly 187% while the market sentiment index shows Extreme Greed. Technically, the 20‑day SMA (4.60) sits beneath both the 50‑day (5.92) and 200‑day (12.25) averages, confirming a bearish trend, yet the RSI of 31.6 signals oversold conditions and the MACD histogram is only marginally negative, suggesting limited downside momentum.
Risk factors include a high debt‑to‑equity ratio (≈153%), sustained operating losses, and a 30‑day volatility near 100%, but the company benefits from a very low beta (0.11), a strong cash position relative to its debt, and upcoming reimbursement opportunities (AMA CPT code effective 2027) that could lift 2026 revenue guidance to ~$39 million.
Risk factors include a high debt‑to‑equity ratio (≈153%), sustained operating losses, and a 30‑day volatility near 100%, but the company benefits from a very low beta (0.11), a strong cash position relative to its debt, and upcoming reimbursement opportunities (AMA CPT code effective 2027) that could lift 2026 revenue guidance to ~$39 million.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 6/10
Key Factors
- Oversold technical indicators (RSI 31.6)
- Recent $10 M capital raise bolstering balance sheet
- Significant quarterly revenue growth (133% YoY)
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Projected 2026 revenue ~ $39 M from CPT code implementation
- Continued shipment ramp‑up of breast acoustic CT systems
- Low market beta reducing systematic risk
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Persistent operating losses and high debt‑to‑equity ratio
- Dependence on regulatory approvals and reimbursement pathways
- Potential for valuation re‑rating if profitability is achieved
Key Metrics & Analysis
Financial Health
Revenue Growth133.40%
Profit Margin-58.94%
ROA-21.83%
Debt/Equity152.78
P/B Ratio12.8
Op. Cash Flow$-9077000
Free Cash Flow$-8550269
Industry P/E24.8
Technical Analysis
TrendBearish
RSI31.6
Support$3.63
Resistance$5.83
MA 20$4.60
MA 50$5.92
MA 200$12.25
MACDBearish
VolumeDecreasing
Fear & Greed Index89.86
Valuation
Target Price$11.60
Upside/Downside187.13%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta0.11
Volatility99.29%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.